en.sedaily.com
Cure8 news brief
Why This Matters
A wider EU pediatric label for a biosimilar of ustekinumab could increase treatment options and access for children with Crohn’s disease or ulcerative colitis, possibly affecting availability and cost.
Families and clinicians managing pediatric IBD may see more prescribing choices and device options (an autoinjector) if the European Commission confirms the CHMP recommendation.
Who Should Pay Attention
Pediatric patients with Crohn’s disease or ulcerative colitis (and their caregivers), clinicians who treat pediatric IBD, and patients interested in biosimilar biologic options or drug-access issues.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
The CHMP (EMA) has recommended expanding the pediatric label for Steqeyma (Celltrion’s ustekinumab biosimilar) to include Crohn’s disease and ulcerative colitis for children aged 2 and older; final approval rests with the European Commission.
The article notes prior approvals for adult indications and limited prior pediatric weight-based approval (children ≥40 kg), plus availability of an autoinjector and Steqeyma’s market uptake in several regions.
What this means: This is a regulatory-step story — CHMP has recommended a label change, which typically precedes final EU approval by the European Commission. If approved, clinicians in EU countries would have a biosimilar ustekinumab option for younger pediatric IBD patients, potentially increasing prescribing choices and access.
The piece is a company-focused business report rather than a clinical study or guideline update. Practical points: The recommendation covers children aged 2 and older and expands beyond the company’s earlier pediatric approval limited by weight (≥40 kg).
The article does not report new trial results, safety data, or changes to dosing; it summarizes the CHMP recommendation and Celltrion’s commercial plans.
Keep In Mind
This article is a business/regulatory news report summarizing a CHMP recommendation; it does not present clinical trial data, new safety findings, or final regulatory approval. Final EU approval requires European Commission sign-off. The report is based on company statements and market context.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationen.sedaily.com
Indexed viaGoogle News
Source typeWeb article
PublishedNov 9, 2026, 12:46 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA approves Stelara for pediatric ulcerative colitis | The Pharmaletter
The FDA approval expands an approved biologic option (ustekinumab/Stelara) to children aged two and older with moderately to severely active ulcerative colitis, giving families and clinicians another treatment choice. It...
FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease
The FDA’s acceptance of Takeda’s sBLA is a regulatory step toward possibly approving IV vedolizumab for children with moderate‑to‑severe UC or Crohn’s. If approved, this would expand an existing adult IBD treatment to...
J&J's Stelara granted EC approval to treat Crohn's disease in paediatric patients - PMLiVE
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.